Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prognostic and therapeutic value of somatic mutations in diffuse large B-cell lymphoma: A systematic review.

Critical reviews in oncology/hematology - 1 Sept 2021

Lopez-Santillan Maria, Lopez-Lopez Elixabet, Alvarez-Gonzalez Paula, Martinez Garazi, Arzuaga-Mendez Javier, Ruiz-Diaz Irune, Guerra-Merino Isabel, Gutierrez-Camino Angela, Martin-Guerrero Idoia

Abstract excerpt

Diffuse large B-cell lymphoma (DLBCL), the most common type of Non-Hodgkin lymphoma (NHL), is a highly heterogeneous and aggressive disease. Regardless of this heterogeneity, all patients receive the same first-line therapy, which fails in 30-40 % of patients, who are either refractory or relapse after remission. With the aim of stratifying patients to improve treatment outcome, different clinical and genetic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Mutational Analysis
Share to Lymphoma, Large B-Cell, Diffuse

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Neoplasm Recurrence, Local

Share to Prognosis

Source

Identifiers

PMID: 34339834
DOI: 10.1016/j.critrevonc.2021.103430

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prognostic and therapeutic value of somatic mutations in diffuse large B-cell lymphoma: A systematic review.PMID 34339834Read ↗

Comprehensive Analysis of TP53 Mutation Characteristics and Identification of Patients with Inferior Prognosis and Enhanced Immune Escape in Diffuse Large B Cell LymphomaSemantic proximity Read ↗

Prognostic impact of TP53 mutations in diffuse large B-cell lymphoma.Semantic proximity Read ↗

Prognostic Impact of TP53 Mutations in Diffuse Large B-Cell LymphomaSemantic proximity Read ↗

Prognostic Analysis of Diffuse Large B-Cell Lymphoma Patients Based on Clinical Characteristics, TP53 Mutation Status, and Number of Co-mutated GenesSemantic proximity Read ↗

TP53 mutations predict poor prognosis in diffuse large B-cell lymphoma: A single-center studySemantic proximity Read ↗

Genetic lesions in diffuse large B-cell lymphomas.Semantic proximity Read ↗

Prognostic impact of MYD88 and TP53 mutations in diffuse large B Cell lymphoma.Semantic proximity Read ↗

TP53 mutation predict poor prognosis in diffuse large B-cell lymphoma: a single-center study.Semantic proximity Read ↗

Molecular Genetics of Relapsed Diffuse Large B-Cell Lymphoma: Insight into Mechanisms of Therapy ResistanceSemantic proximity Read ↗

Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell LymphomaSemantic proximity Read ↗

A Novel CD58 Mutation-Related Signature Predicts Prognosis Risk in Diffuse Large B-Cell Lymphoma Patients.Semantic proximity Read ↗

Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.